NewAmsterdam Pharma (NASDAQ:NAMS) Coverage Initiated at HC Wainwright

HC Wainwright assumed coverage on shares of NewAmsterdam Pharma (NASDAQ:NAMS) in a report issued on Monday morning, MarketBeat Ratings reports. The brokerage issued a buy rating and a $48.00 price objective on the stock. HC Wainwright also issued estimates for NewAmsterdam Pharma’s Q4 2024 earnings at ($0.37) EPS, FY2024 earnings at ($1.64) EPS, Q1 2025 earnings at ($0.45) EPS, Q2 2025 earnings at ($0.43) EPS, Q3 2025 earnings at ($0.48) EPS, Q4 2025 earnings at ($0.52) EPS, FY2025 earnings at ($1.88) EPS, FY2026 earnings at ($1.80) EPS, FY2027 earnings at ($1.78) EPS and FY2028 earnings at ($1.04) EPS.

A number of other research analysts have also recently weighed in on NAMS. Needham & Company LLC reissued a “buy” rating and set a $36.00 price objective on shares of NewAmsterdam Pharma in a research note on Thursday, December 5th. Piper Sandler reissued an “overweight” rating and issued a $37.00 price target on shares of NewAmsterdam Pharma in a report on Monday, September 23rd. Royal Bank of Canada restated an “outperform” rating and issued a $31.00 price objective on shares of NewAmsterdam Pharma in a research report on Thursday, September 5th. Finally, Scotiabank lifted their price objective on NewAmsterdam Pharma from $35.00 to $47.00 and gave the stock a “sector outperform” rating in a research report on Wednesday, December 11th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, NewAmsterdam Pharma presently has an average rating of “Buy” and an average target price of $38.17.

NewAmsterdam Pharma Stock Performance

NASDAQ:NAMS opened at $25.70 on Monday. The firm has a 50-day moving average price of $22.26 and a two-hundred day moving average price of $19.26. NewAmsterdam Pharma has a twelve month low of $11.18 and a twelve month high of $27.29.

Insiders Place Their Bets

In other news, major shareholder Nap B.V. Forgrowth sold 8,530 shares of the company’s stock in a transaction dated Friday, November 15th. The shares were sold at an average price of $25.02, for a total transaction of $213,420.60. Following the completion of the transaction, the insider now owns 11,812,033 shares of the company’s stock, valued at $295,537,065.66. This represents a 0.07 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders have sold a total of 416,884 shares of company stock valued at $10,676,428 in the last quarter. 19.50% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On NewAmsterdam Pharma

Hedge funds have recently modified their holdings of the stock. Frazier Life Sciences Management L.P. raised its stake in NewAmsterdam Pharma by 5.1% during the third quarter. Frazier Life Sciences Management L.P. now owns 12,855,194 shares of the company’s stock worth $213,396,000 after purchasing an additional 628,251 shares during the period. Janus Henderson Group PLC increased its holdings in shares of NewAmsterdam Pharma by 51.1% during the 3rd quarter. Janus Henderson Group PLC now owns 1,540,729 shares of the company’s stock worth $25,607,000 after buying an additional 520,772 shares during the last quarter. Decheng Capital LLC purchased a new position in shares of NewAmsterdam Pharma in the 2nd quarter worth $7,684,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in NewAmsterdam Pharma by 1,231.0% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 239,283 shares of the company’s stock valued at $3,972,000 after acquiring an additional 221,305 shares during the last quarter. Finally, Millennium Management LLC grew its position in NewAmsterdam Pharma by 23.0% during the second quarter. Millennium Management LLC now owns 1,165,429 shares of the company’s stock valued at $22,388,000 after acquiring an additional 217,902 shares during the period. 89.89% of the stock is owned by institutional investors and hedge funds.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.